Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05462639 Available - Multiple Myeloma Clinical Trials

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

MAGNETISMM17
Start date: n/a
Phase:
Study type: Expanded Access

Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity. This expanded access protocol will provide access to elranatamab until it becomes commercially accessible to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.

NCT ID: NCT05346835 Available - Multiple Myeloma Clinical Trials

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.

NCT ID: NCT05164250 Available - Multiple Myeloma Clinical Trials

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Start date: n/a
Phase:
Study type: Expanded Access

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

NCT ID: NCT03763370 Available - Multiple Myeloma Clinical Trials

Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma